To evaluate the role of ABCB1 and CYP2C19 variants on major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) treated with clopidogrel.
Approach:
Study Design: Retrospective cohort study involving 174 patients with ACS treated with clopidogrel.
Genotyping: Performed using real-time PCR® TaqMan assays for ABCB1 and CYP2C19 variants.
Statistical Analysis: Associations with 1-year MACE were assessed using genotype, carrier status, and multivariable logistic regression.
Key Findings:
Minor allele frequencies for ABCB1 variants were 48.85% (rs1045642), 50% (rs2032582), and 51.44% (rs1128503).
No significant correlation between ABCB1 alleles and MACE outcomes (p-value > 0.05).
CYP2C19*2 showed a weak trend of increased risk of MACE (RR = 1.41; 95% CI: 0.95–2.10; p-value = 0.08).
CYP2C19*3 (1.15%) was not significantly related to any outcomes.
Only age showed a non-significant trend toward higher risk in multivariable analysis.
Interpretation:
The study found no significant link between common ABCB1 variants and MACE in clopidogrel-treated ACS patients from the UAE.
Limitations:
Retrospective design may limit causal inferences.
Sample size may not be sufficient to detect small effect sizes.
Findings may not be generalizable beyond the UAE population.
Conclusion:
The study did not find significant predictors of MACE outcomes from ABCB1 variants in the studied population.
by Lubna Q. Khasawneh, Mais N. Alqasrawi, Zeina N. Al-Mahayri, Lilas Dabaghie, Sahar M. Altoum, Gohar Jamil, Salahdein Aburuz, Dana Hamza, Lizy George, Faiz Al-Bakshy, Kaes Al-Anee, Khuzama AlAhamad, Fatma Al-Maskari, Husam Ouda, Juma AlKaabi, George P. Patrinos, Bassam R. Ali
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
